Catalio Capital Management, LP
Q2 2026 13F filing
Updated 83 days ago39 disclosed positions worth $532.1M
Full holdings
Every line item disclosed in Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | A AVALYN PHARMACEUTICALS INC | $55.2M | 1.68M | 10.37% | — |
| 2 | J JOHNSON & JOHNSON | $35.3M | 138.9K | 6.63% | — |
| 3 | G GILEAD SCIENCES INC | $34M | 269.3K | 6.39% | Added(+64.3%) |
| 4 | B BRIDGEBIO PHARMA INC | $33.9M | 455.0K | 6.37% | Added(+5.3%) |
| 5 | S SYNDAX PHARMACEUTICALS INC | $26.6M | 1.22M | 4.99% | Added(+16.5%) |
| 6 | D DEFINIUM THERAPEUTICS INC | $26.5M | 562.7K | 4.97% | Trimmed(-45.8%) |
| 7 | C BRISTOL-MYERS SQUIBB CO | $23.8M | 413.0K | 4.47% | Trimmed(-1.9%) |
| 8 | P PARABILIS MEDICINES INC | $22.6M | 824.0K | 4.24% | — |
| 9 | N NATERA INC | $22.3M | 82.2K | 4.19% | Added(+15.9%) |
| 10 | I INCYTE CORP | $21.7M | 191.6K | 4.08% | Added(+5.2%) |
| 11 | S SEPTERNA INC | $18M | 536.2K | 3.37% | Added(+82.1%) |
| 12 | M MINERALYS THERAPEUTICS INC | $17.5M | 648.7K | 3.29% | Added(+47.8%) |
| 13 | H HEARTFLOW INC | $17.1M | 583.1K | 3.21% | Added(+44.5%) |
| 14 | C CORVUS PHARMACEUTICALS INC | $16.1M | 1.08M | 3.03% | Added(+21.2%) |
| 15 | G STRUCTURE THERAPEUTICS INC | $14.8M | 276.6K | 2.79% | Added(+8.3%) |
| 16 | P PROTAGONIST THERAPEUTICS INC | $13.1M | 106.8K | 2.46% | — |
| 17 | I DISC MEDICINE INC | $11.7M | 159.4K | 2.19% | Added(+29.6%) |
| 18 | E EDWARDS LIFESCIENCES CORP | $11.3M | 124.8K | 2.12% | Trimmed(-13.7%) |
| 19 | A AXSOME THERAPEUTICS INC. | $10.6M | 43.2K | 1.99% | — |
| 20 | R ULTRAGENYX PHARMACEUTICAL IN | $10.6M | 316.3K | 1.98% | Trimmed(-62.8%) |
| 21 | K KAILERA THERAPEUTICS INC | $10.3M | 468.8K | 1.94% | — |
| 22 | K KARYOPHARM THERAPEUTICS INC | $9.2M | 940.9K | 1.73% | Added(+4.8%) |
| 23 | O ODYSSEY THERAPEUTICS INC | $8.6M | 457.8K | 1.61% | — |
| 24 | A ASCENDIS PHARMA A/S | $8.5M | 31.8K | 1.59% | — |
| 25 | ? N/A KARDIGAN INC | $7.5M | 312.5K | 1.40% | — |
| 26 | E ELEDON PHARMACEUTICALS INC | $6.7M | 1.70M | 1.26% | Added(+3.4%) |
| 27 | F 4D MOLECULAR THERAPEUTICS IN | $6.3M | 471.3K | 1.18% | — |
| 28 | M VERADERMICS INC | $5.6M | 45.9K | 1.06% | Trimmed(-73.6%) |
| 29 | D DYNE THERAPEUTICS INC | $5.4M | 244.9K | 1.02% | Trimmed(-13.4%) |
| 30 | G FRACTYL HEALTH INC | $4.9M | 6.17M | 0.92% | Added(+12.3%) |
| 31 | I IMMUNOCORE HLDGS PLC | $4.7M | 148.0K | 0.88% | Added(+75.5%) |
| 32 | D DIANTHUS THERAPEUTICS INC | $3.2M | 32.9K | 0.60% | Trimmed(-94.1%) |
| 33 | ? N/A BRIDGEBIO ONCOLOGY THERAPEUT | $2.4M | 318.4K | 0.46% | — |
| 34 | T PROTARA THERAPEUTICS INC | $2M | 520.1K | 0.37% | Trimmed(-10.3%) |
| 35 | ? N/A HYPERFINE INC | $1.8M | 1.32M | 0.33% | Unchanged |
| 36 | A ATAIBECKLEY INC | $1M | 196.9K | 0.20% | Unchanged |
| 37 | M METAGENOMI THERAPEUTICS INC | $630K | 529.0K | 0.12% | Unchanged |
| 38 | ? N/A OUTSET MED INC | $511K | 118.3K | 0.10% | Unchanged |
| 39 | F FAETH THERAPEUTICS INC | $368K | 14.7K | 0.07% | Unchanged |